Related Experiment Video
Updated: Jul 30, 2025
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Advanced immunotherapies for glioblastoma: tumor neoantigen vaccines in combination with immunomodulators
Berta Segura-Collar1,2, Sara Hiller-Vallina1,2, Olaya de Dios1,3
1Instituto de Investigaciones Biomédicas I+12, Hospital Universitario, 12 de Octubre, 28041, Madrid, Spain.
Abstract:
Glial-origin brain tumors, including glioblastomas (GBM), have one of the worst prognoses due to their rapid and fatal progression. From an oncological point of view, advances in complete surgical resection fail to eliminate the entire tumor and the remaining cells allow a rapid recurrence, which does not respond to traditional therapeutic treatments. Here, we have reviewed new immunotherapy strategies in association with the knowledge of the immune micro-environment. To understand the best lines for the future, we address the advances in the design of neoantigen vaccines and possible new immune modulators. Recently, the efficacy and availability of vaccine development with different formulations, especially liposome plus mRNA vaccines, has been observed. We believe that the application of new strategies used with mRNA vaccines in combination with personalized medicine (guided by different omic's strategies) could give good results in glioma therapy. In addition, a large part of the possible advances in new immunotherapy strategies focused on GBM may be key improving current therapies of immune checkpoint inhibitors (ICI), given the fact that this type of tumor has been highly refractory to ICI.
Insights
New immunotherapy strategies, including mRNA vaccines and personalized medicine, show promise for treating aggressive glioblastomas (GBM). These approaches aim to overcome resistance to traditional therapies and immune checkpoint inhibitors in brain tumors.
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Therapy
Background:
- Glial-origin brain tumors, particularly glioblastomas (GBM), present a poor prognosis due to rapid progression and recurrence.
- Complete surgical resection is insufficient, as residual tumor cells resist conventional treatments.
Purpose of the Study:
- To review novel immunotherapy strategies for GBM, considering the tumor's immune microenvironment.
- To explore advancements in neoantigen vaccines and immune modulators for future therapeutic lines.
Main Methods:
- Literature review of current immunotherapy research for glial-origin brain tumors.
- Analysis of emerging vaccine technologies, focusing on mRNA and liposomal formulations.
- Evaluation of personalized medicine approaches guided by omics strategies.
Main Results:
- Recent vaccine developments, especially liposome plus mRNA formulations, demonstrate significant efficacy.
- Personalized medicine combined with mRNA vaccines offers potential for improved glioma therapy.
- GBM's refractoriness to immune checkpoint inhibitors (ICI) highlights the need for advanced immunotherapy.
Conclusions:
- Novel immunotherapy strategies, particularly mRNA vaccines and personalized medicine, hold promise for enhancing GBM treatment.
- Further research into immune modulators and overcoming ICI resistance is crucial for improving patient outcomes in neuro-oncology.
More Related Videos
11:15Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Related Concept Videos
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...